Emcure Pharmaceuticals · NSE: EMCURE · BSE: 544210
Q1 FY25 results · Apr–Jun 2024
Emcure Pharmaceuticals reported revenue from operations of ₹1,815.14 crore and net profit of ₹152.59 crore for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,815.14 | — | — | — | — |
| Other income | 23.44 | — | — | — | — |
| Total income | 1,838.58 | — | — | — | — |
| Profit before tax | 207.41 | — | — | — | — |
| Net profit for the period | 152.59 | — | — | — | — |
| Attributable to shareholders of the company | 144.08 | — | — | — | — |
| EPS, basic (₹) | 7.95 | — | — | — | — |
| Net margin (%) | 8.4 | — | — |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 970.29 | — | — | — | — |
| Other income | 32.51 | — | — | — | — |
| Total income | 1,002.80 | — | — | — | — |
| Profit before tax | 55.05 | — | — | — | — |
| Net profit for the period | 40.45 | — | — | — | — |
| EPS, basic (₹) | 2.23 | — | — | — | — |
| Net margin (%) | 4.2 | — | — |
Consolidated
- Filed with BSE
- 27 Aug 2024, 10:46 IST
- Board meeting
- 13 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Aug 2024, 10:46 IST
- Board meeting
- 13 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE